The IL-1β Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure

Visual Abstract
Highlights • Immediate IL-1β antibody gevokizumab administration reduces ischemia/reperfusion related infarct size. • Immediate and late IL-1β antibody gevokizumab administration improves heart failure related left ventricular remodeling. • IL-1β antibody gevokizumab improves heart failure related coronary dysfunction.
Summary This study reports preclinical data showing that the interleukin (IL)-1β modulation is a new promising target in the pathophysiological context of heart failure. Indeed, in nondiabetic Wistar and diabetic Goto-Kakizaki rats with chronic heart failure induced by myocardial infarction, administration of the IL-1β antibody gevokizumab improves ‘surrogate’ markers of survival (i.e., left ventricular remodeling, hemodynamics, and function as well as coronary function). However, whether IL-1β modulation per se or in combination with standard treatments of heart failure improves long-term outcome in human heart failure remains to be determined.